Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.

@article{Greenblatt2013ComparisonOP,
  title={Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.},
  author={D. Greenblatt and J. Harmatz and T. Roth and Nikhilesh N. Singh and M. Moline and S. Harris and R. Kapil},
  journal={Clinical therapeutics},
  year={2013},
  volume={35 5},
  pages={
          604-11
        }
}
BACKGROUND A zolpidem sublingual tablet (ZST) formulation was recently approved by the US Food and Drug Administration to treat middle-of-the-night (MOTN) awakening with difficulty returning to sleep. OBJECTIVE The aim of this study was to compare the zolpidem pharmacokinetic profiles of 3.5-mg ZST and 10-mg immediate-release (IR) oral zolpidem in healthy female and male adults. METHODS This randomized, open-label crossover study compared the pharmacokinetic profile of ZST with that of IR… Expand
Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects
TLDR
Elderly individuals were found to have higher Cmax and AUC values compared with non-elderly subjects and area under the plasma concentration–time curve (AUC), maximum observed concentration (Cmax), time to reach Cmax, elimination half-life (T½), and apparent oral clearance (CL/F). Expand
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets
TLDR
It is suggested that administration of ZST in the fed state is not optimal for maximizing the likelihood of therapeutic benefit and minimizing the probability of residual sedation. Expand
Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans.
TLDR
It could be concluded that ZNS is safe and well tolerated over the evaluated range of intranasal doses and generally higher in female subjects than that in male subjects. Expand
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration
TLDR
It is confirmed that zolpidem clearance is lower in females than in males, and PD effects of zolPidem from ZST are greater in female subjects, due to a combination of higher plasma concentrations and greater intrinsic sensitivity. Expand
Zolpidem Sublingual Formulations
TLDR
Two recently developed sublingual formulation of zolpidem that specifically target sleep-onset insomnia and middle-of-the-night (MOTN) insomnia are discussed, which have a comparable elimination half-life but a somewhat shorter Tmax than the standard oral form. Expand
Mechanistic investigation of the negative food effect of modified release zolpidem
TLDR
It is demonstrated that a combination of biorelevant dissolution testing with modeling approaches enables a mechanistic understanding of the absorption of zolpidem from various formulations and can serve as a useful biopharmaceutical approach for the development of modified release solid oral dosage forms. Expand
Zolpidem's use for insomnia.
TLDR
The clinical pharmacology, indications and uses of Zolpidem, identifying withdrawal symptoms, abuse and dependence potentials, and adverse drug reactions are discussed. Expand
Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial
TLDR
The safety and efficacy of both zolpidem formulations are comparable, and the sublingual 5 mg dose induced sleep more rapidly, compared to the oral dose, at bedtime and “as needed” following middle-of-the-night awakenings. Expand
Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem
TLDR
The novel physiologically based IO absorption OCCAT™ model showed satisfactory performance and will be helpful to guide development of future intraoral formulations. Expand
Zolpidem and Gender: Are Women Really At Risk?
TLDR
Dose reduction in women of zolpidem is not supported by available scientific evidence, and may in fact lead to underdosing and the consequent hazard of inadequately treated insomnia. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.
TLDR
Low-dose sublingual zolpidem tartrate may be suitable for treatment of patients who have difficulty resuming sleep after MOTN awakenings, and was generally safe and well tolerated in this Randomized, double-blind, placebo-controlled, 3-way crossover study. Expand
Dynamics and Kinetics of a Modified‐Release Formulation of Zolpidem: Comparison With Immediate‐Release Standard Zolpidem and Placebo
TLDR
Modified‐release zolpidem produces sustained plasma levels compared to IR, with resulting enhancement of pharmacodynamic effects in the 3‐ to 6‐hour post‐dosage interval. Expand
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
TLDR
The clinical and in vitro data suggest that reduced free serum testosterone may have a modulatory role in age-dependent changes in zolpidem pharmacokinetics in men and recommendations of lower clinical doses of zolPidem in the elderly are consistent with recommendations. Expand
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
TLDR
The complete dependence of triazolam clearance on CYP3A activity, as opposed to the mixed CYP participation in zolpidem clearance, may explain the differing sex effects on clearance of the two compounds. Expand
Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects
TLDR
Zolpidem reduced saccadic peak velocity, adaptive tracking performance, electroencephalogram (EEG) alpha power and visual analogue scale (VAS) alertness score and increased body sway, EEG beta power and VAS ‘feeling high’ and central nervous system effects normalised more rapidly than the decrease of plasma concentrations. Expand
Zolpidem Extended-Release
TLDR
Zolpidem CR was generally well tolerated and appears to have a tolerability profile similar to that of the original formulation of zolpIDs, a nonbenzodiazepine hypnotic indicated for the treatment of insomnia. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem
TLDR
Zolpidem is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults. Expand
Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
TLDR
While zolpidem aids sedation, and may reduce memory or psychomotor function within the first 2 hours after administration of single oral doses, its use as a surgical premedicant remains to be established. Expand
Zolpidem for insomnia
TLDR
approved doses of zolpidem are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia, however, favorable effects on sleep maintenance are observed less consistently. Expand
Sublingual zolpidem tartrate lozenge for the treatment of insomnia
  • A. Lankford
  • Medicine
  • Expert review of clinical pharmacology
  • 2009
TLDR
Publishing data suggest that SZT is generally safe and effective at rapidly inducing sedation without residual next-day effects, as long as the patient has at least 4 h remaining in bed at the time of administration. Expand
...
1
2
...